natgillin/translations-raw huggingface dataset:
‘Less conservative calculation’ differs from the ‘very conservative calculation’ in one aspect: If wound closure was not observed in a wound half photo series, it was calculated to have occurred not one day, but approximately 3 days later (the mean time interval between wound dressing changes in the studies).
„Manj konzervativen izračun“ se razlikuje od „zelo konzervativnega izračuna“ v enem pogledu: Če zaprtje rane ni bilo zabeleženo v seriji fotografij polovice rane, so izračunali, da je do zaprtja ni prišlo en dan po zadnji fotografiji v seriji, temveč 3 dni kasneje (povprečni časovni interval med zamenjavo povoja rane v študijah).
‘non-metastatic’ means that it is at an early stage and has not spread far within the body.
„nemetastatski“ pa pomeni, da je v zgodnji fazi in da se ni razširil daleč po telesu.
‘Ocular hypertension’ is when the pressure in the eye is higher than normal.
Očesna hipertenzija je stanje, pri katerem je tlak v očesu višji od običajnega.
‘oral anticoagulants’ often referred to as ‘blood thinners’ which include warfarin.
"peroralne antikoagulante" (pogosto jih imenujejo "zdravila za redčenje krvi"), med katere
‘Other STS’ subgroups
Podskupina "drugi STS"
‘Other STS’ subgroups* Median (months)
Podskupine "drugi STS"* Mediana (meseci)
‘Primary’ vs. ‘secondary’ blinded read: In the primary blinded read evaluation a rigorous quality check was implemented to assure blinding of the observers.
"Primarno" vs. "sekundarno" slepo ocenjevanje: Pri primarnem slepem ocenjevanju so za zagotovitev slepote opazovalcev opravili strog nadzor kakovosti.
‘Remsima is a ‘biosimilar’ medicine.
Remsima je „biološko podobno“ zdravilo.
‘Sorbitol special-glycerin blend’ (d-sorbitol, 1,4 sorbitan, mannitol and glycerin) Titanium dioxide (E171)
'mešanica posebnega sorbitola in glicerola' (d-sorbitol, 1,4 sorbitan, manitol in glicerol) titanov dioksid (E171)
‘surface antigen’ (proteins from the surface) of the hepatitis B virus.
„površinski antigen“ (beljakovino površine) virusa hepatitisa B.
’Very conservative calculation’ means that the first observation of wound closure was taken as time of wound closure.
„Zelo konzervativen izračun“ pomeni, da je bilo prvo zaprtje rane zabeleženo ob zaprtju rane.
“+” Denotes a censored observation.
“+” označuje krnjene podatke
“10 pre-filled syringe (0.5 ml) + 10 alcohol swabs”
“10 napolnjenih injekcijskih brizg (0,5 ml) + 10 alkoholnih krpic”
“13.3 mg/24 h” and “CNFU”.
“13.3 mg/24 h” in “CNFU”.
“4.6 mg/24 h” and “AMCX”,
“4.6 mg/24 h” in “AMCX”,
“4.6 mg/24 h” and “AMCX”.
“4.6 mg/24 h” in “AMCX”.
“9.5 mg/24 h” and “BHDI”,
“9.5 mg/24 h” in “BHDI”,
“9.5 mg/24 h” and “BHDI”.
“9.5 mg/24 h” in “BHDI”.
“Angioedema”
„Angioedem“
“Bad” cholesterol is normally removed from your blood by binding to specific “receptors” (docking stations) in your liver.
"Slabi" holesterol se običajno odstranjuje iz krvi z vezavo na specifične "receptorje" (vezavna mesta) v jetrih.
“beta2 stimulants” (for example ritodrine, salbutamol or terbutaline),
“stimulatorje receptorjev beta2” (na primer ritodrin, salbutamol ali terbutalin),
“beta2 stimulants”such as salbutamol or terbutaline to treat asthma, or ritodrine used to stop premature labor,
“stimulatorje receptorjev beta2” (kot sta salbutamol ali terbutalin) za zdravljenje astme, ali ritodrin za ustavljanje predčasnega poroda,
“click”
“klik“
“compartment syndrome”, a medical condition characterised by pain, swelling and neurological symptoms, as well as muscle damage in the affected arm or leg
“utesnitveni sindrom”, zdravstveno stanje z značilno bolečino, oteklino in nevrološkimi simptomi, kot tudi poškodbami mišice v prizadeti roki ali nogi;
“Cumulatively” means since the use of the vaccine; events not reported during the period of interest should not be presented in the tables.
"Kumulativno" pomeni od uporabe cepiva; učinki, ki niso prijavljeni med proučevanim obdobjem, ne smejo biti vključeni v preglednice.
“Cumulatively” means since the use of the vaccine; events not reported during the period of interest should not be presented in the tables.
”Kumulativno” pomeni v času od uporabe cepiva; morebitni dogodki oz. učinki, ki niso prijavljeni v proučevanem obdobju, pa ne smejo biti podani v preglednicah.
“Cumulatively” means since the use of the vaccine; events not reported during the period of interest should not be presented in the tables.
„Kumulativno“ pomeni od začetka uporabe cepiva; dogodki, o katerih v obdobju interesa niso poročali, se v teh tabelah ne predstavijo.
“FTY0.5mg” is imprinted on the cap with black ink and two bands are imprinted on the body with yellow ink.
Na pokrovčku je s črnim barvilom natisnjena oznaka ”FTY0.5mg”, na telesu kapsule pa sta z rumenim barvilom natisnjena dva obroča.
“haemolytic uraemic syndrome” when red blood cells breakup (hemolysis) which may happen with or without kidney failure
hemolitično-uremični sindrom, ki se pojavi zaradi razpadanja rdečih krvnih celic (hemoliza), lahko z odpovedjo ledvic ali brez nje
“m” is medians in months.
“m” predstavlja mediane v mesecih.
“Neisseria meningitidis" types A, C, W-135 and Y bacteria can cause serious illnesses such as
Bakterije “Neisseria meningitidis" tipov A, C, W-135 in Y lahko povzročijo resne bolezni, na primer:
“Neisseria meningitidis" types A, C, W-135 and Y bacteria can cause serious illnesses such as:
Bakterije “Neisseria meningitidis" tipov A, C, W-135 in Y lahko povzročijo resne bolezni, na primer:
“Nephrotic syndrome is included in section 4.8 of the SmPC as an ADR with frequency “uncommon”.
“Nefrotični sindrom je naveden v točki 4.8 SmPC-ja kot ADR s pogostnostjo “redek”.
“n” reflects enrolled patients
“n”: število vključenih bolnikov
“oedema peripheral” includes “injection site oedema” and “oedema”
“periferni edem” vključuje “edem na mestu injiciranja” in “edem”
“Off” time (hrs)*
Čas »izklopa« (h)
“On” time without troublesome dyskinesia (hrs)*
Čas »vklopa« brez moteče diskinezije (h)
“pancytopenia” low level of all blood cells (red and white blood cells and platelets) shown in blood tests
pancitopenija – nizko število vseh krvnih celic (rdečih in belih krvnih celic ter trombocitov) – ki se pokaže na preiskavah krvi
“Patients with naïve use of ENF” are patients who used ENF for the first time
“bolniki, ki so prvič jemali ENF” so bolniki, ki so v preskušanju prvič uporabili ENF
“Patients with no/non-naïve use of ENF” are patients who did not use ENF or who used ENF but not for the first time
“bolniki, ki še niso/niso prvič jemali ENF” so bolniki, ki še niso jemali ENF ali pa so ga uporabljali, vendar ne prvič
“Preliminary results of the HYDREP study were provided in March 2013.
»Predhodni rezultati študije HYDREP so bili predloženi marca 2013.
“Primary” means that the hyperparathyroidism is not caused by any other condition and “secondary” means that the hyperparathyroidism is caused by another condition, e.g. kidney disease.
"Primarni" pomeni, da hiperparatiroidizma ne povzroča kakšna druga bolezen, "sekundarni" pa pomeni, da ga povzroča neka druga bolezen, npr. bolezen ledvic.
“Primary” means that the hyperparathyroidism is not caused by any other condition and “secondary” means that the hyperparathyroidism is caused by another condition, e.g., kidney disease.
"Primarni" pomeni, da hiperparatiroidizma ne povzroča kakšna druga bolezen, "sekundarni" pa pomeni, da ga povzroča neka druga bolezen, npr. bolezen ledvic.
“Pull here”
“Povlecite tukaj.”
“Relief was defined as no or only mild symptoms at week 12.
„Olajšanje je bilo opredeljeno kot brez simptomov ali le z blagimi simptomi v 12. tednu.
“Serotonin syndrome” (a rare reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles), fits
“serotoninski sindrom” (redka reakcija, ki lahko povzroči občutke velike sreče, zaspanost, nerodnost, nemir, občutek pijanosti, vročino, znojenje ali togost mišic), epileptični napadi
“Serotonin syndrome” (a rare reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles), fits
“serotoninski sindrom” (redka reakcija, ki lahko povzroči občutke velike sreče, zaspanost, okornost, nemir, občutek pijanosti, vročino, znojenje ali toge mišice), epileptični napadi
“Serotonin syndrome” (a rare reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles), fits, sudden involuntary jerks or twitches of the muscles, sensation of restlessness or an inability to sit or stand still, difficulty controlling movement e.g. lack of coordination or involuntary movements of the muscles, restless legs syndrome
erotoninski sindrom” (redka reakcija, ki lahko povzroči občutke velike sreče, zaspanost, okornost, nemir, občutek pijanosti, vročino, znojenje ali toge mišice), epileptični napadi, nenadni nehoteni gibi mišic ali mišično trzanje, občutek nemira ali nezmožnosti sedenja ali stanja pri miru, težave z nadziranjem gibov, npr. slaba koordinacija ali nehoteni gibi mišic, sindrom nemirnih nog
“Serotonin syndrome” (a rare reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles), fits;
“serotoninski sindrom” (redka reakcija, ki lahko povzroči občutke velike sreče, zaspanost, okornost, nemir, občutek pijanosti, vročino, znojenje ali toge mišice), epileptični napadi;
“skin laceration” includes “injection site laceration” and “laceration”
“raztrganina kože” vključuje “raztrganino na mestu injiciranja” in “raztrganino”
“SNAP”
“TLES K”
“SNAP”
“TLESK
“STN 12.5 mg” on the body, and containing yellow to orange granules.
Kapsule vsebujejo rumena do oranžna zrnca.
“STN 12.5 mg” on the body, containing yellow to orange granules.
Kapsule vsebujejo rumena do oranžna zrnca.
“STN 37.5 mg” on the body, and containing yellow to orange granules.
Kapsule vsebujejo rumena do oranžna zrnca.
“STN 37.5 mg” on the body, containing yellow to orange granules.
Kapsule vsebujejo rumena do oranžna zrnca.
“Syndrome of inappropriate antidiuretic hormone secretion”, which is a condition that causes low levels of blood sodium tumour pain.
»sindrom neustreznega izločanja antidiuretičnega hormona« - stanje, ki povzroči nizke ravni natrija v krvi, tumorska bolečina.
“To be attached to the patient’s medical record: Cyanokit has been administered to this patient.
“V bolnikovo zdravstveno kartoteko je treba priložiti naslednje: Ta bolnik je prejel zdravilo Cyanokit.
“Urinary retention” is a known class effect of anticholinergic drugs (Halpin, 2015 Stephenson, 2011; Afonso, 2011) and a warning is already included in the SmPC recommending the use of UMEC/VI with caution in patients with urinary retention.
“Zastoj urina" je znan učinek skupine antiholinergičnih zdravil (Halpin, 2015 Stephenson, 2011; Afonso, 2011) in opozorilo je že vključeno v povzetek glavnih značilnosti zdravila, ki priporoča previdnost pri uporabi kombinacije UMEK/VI pri bolnikih z zastajanjem urina.
“Є” on the cap, and “LENV 4 mg” on the body.
14,3 mm in ima s črnim črnilom izpisano oznako »Є« na pokrovčku kapsule in »LENV 4 mg« na telesu kapsule.
↑ 11%
zdravila
↑ 19%
zdravila
↑ 39%
Antiastmatik
↑ 4%
Teofilin1
↑ 5 fold
↑ 5-krat
↑ 5%
Afatinib
↑ alfentanil
↑ alfentanila
↑ alprazolam
0,98
↑ alprazolam
↑ alprazolama
↑ amlodipine
↑ amlodipina
↑ antibacterials inhibition of CYP3A
↑ antibiotikov zaviranje CYP3A
↑ atazanavir
↑ atazanavirja
↑ atorvastatin
↑ atorvastatina
↑ AUC 1.19 (0.98, 1.45)
↑ AUC 1,13 (0,81; 1,57)
↑ bosentan
↑ bosentana
↑ budesonide inhibition of CYP3A
↑ budezonida zaviranje CYP3A
↑ colchicine inhibition of CYP3A
↑ kolhicina zaviranje CYP3A
↑ cyclosporine
↑ ciklosporina
↑ digoxin
↑ digoksina
↑ domperidone inhibition of CYP3A
↑ domperidona zaviranje CYP3A
↑ erythromycin
↑ paritaprevir
↑ fentanyl
↑ fentanila
↑ fluticasone
↑ flutikazona
↑ fusidic acid
↑ fusidna kislina
↑ keto-
↑ ketokonazol
↑ ketoconazole (200 mg)
↑ ketokonazola (200 mg)
↑ ketoconazole (400 mg)
↑ ketokonazola (400 mg)
↑ lidocaine inhibition of CYP3A
↑ lidokaina zaviranje CYP3A
↑ metformin inhibition of MATE-1 and MATE2-K
↑ metformina zaviranje MATE-1 in MATE2-K
↑ midazolam (p.o.)
↑ midazolama (i.v.) AUC 3,40 (3,04-3,79)
↑ midazolam or triazolam
↑ midazolam ali triazolam
↑ nor- elgestromi ne
↑ norelgestromi n
↑ nor- elgestromine
↑ norelgestromi n
↑ norbu- prenorphine
norbuprenorfi n
↑ norbu- prenorphine
↑ norbuprenorfi n
↑ or ↓ fexofenadine
fenobarbital, fenitoin ↓ IVA
↑ or ↓ phenobarbital induction of CYP3A by phenobarbital, and inhibition of CYP3A by telaprevir
↑ ali ↓ fenobarbitala indukcija CYP3A s fenobarbitalom in zaviranje CYP3A s telaprevirjem
↑ or ↓ ranitidine
↑ ali ↓ ranitidin
↑ or ↓ voriconazole
↑ ali ↓ vorikonazola
↑ or ↓ warfarin modulation of metabolic enzymes
↑ ali ↓ varfarina modulacija presnovnih encimov
↑ paritaprevir
(0,94-1,57)
↑ paritaprevir
eritromicinom,
↑ PDE-5 inhibitors inhibition of CYP3A
↑ zaviralcev PDE-5 zaviranje CYP3A
↑ phenytoin
↑ fenitoina
↑ pimozide, quetiapine
↑ primozid, kvetiapin
↑ posaconazole
↑ posakonazola
↑ quinidine
↑ kinidin
↑ raltegravir
↑ raltegravirja
↑ repaglinide
paritaprevirjem
↑ rilpivirine (+ TVR
↑ rilpivirin (+ TVR 750 mg
↑ S- Desmethyl citalopram
↑ S- dezmetilcitalo pram
↑ salmeterol inhibition of CYP3A
↑ salmeterola zaviranje CYP3A
↑ statin
↑ statina
↑ Statins
↑ Statini
↑ Sulfameth-
↑ sulfametoksaz ol
↑ tacrolimus
↑ takrolimusa
↑ telaprevir
↑ telaprevirja
↑ telaprevir (with
↑ telaprevirja (ob uporabi
↑ tenofovir
↑ tenofovirja
↑ Trazodone
↑ trazodon
↑ trazodone inhibition of CYP3A
↑ trazodona zaviranje CYP3A
↑ trimethoprim
↑ trimetoprim
↑2.5 fold ↔
4.3.
↑2.5 fold ↔
Buspiron
↑Fluticasone
flutikazon
↑in plasma concentrations of Dasatinib have been observed Dabrafenib
Opazili so ↑ koncentracij dasatiniba v plazmi.
↑in plasma concentrations of nadolol have been observed
Opazili so ↑ koncentracij nadolola v plazmi.
↑in plasma concentrations of these drugs have been observed
Opazili so ↑ koncentracij teh zdravil v plazmi.
↑in plasma concentrations of tolterodine have been observed
Opazili so ↑ koncentracij tolterodina v plazmi.
↑in plasma concentrations of tolvaptan have been observed
Opazili so ↑ koncentracij tolvaptana v plazmi.
→ Ask your doctor or pharmacist for advice if you take more tablets than prescribed.
Posvetujte se s svojim zdravnikom ali s farmacevtom, če ste vzeli več tablet, kot vam je predpisal zdravnik.
→ Don’t breast-feed while you're taking Volibris.
→ Med jemanjem zdravila Volibris ne smete dojiti.
→ Don’t drive or use machines if you’re feeling unwell.
→ Ne upravljajte vozil ali strojev, če se ne počutite dobro.
→ Don’t stop taking Volibris unless you have agreed this with your doctor.
→Ne prenehajte z jemanjem zdravila Volibris brez nasveta zdravnika.
→ Don’t take two doses at the same time to make up for a forgotten dose.
→ Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
→ Don’t take Volibris if you are pregnant or planning to become pregnant.
→ Ne jemljite zdravila Volibris, če ste noseči ali nameravate zanositi.
→ If it is possible you could become pregnant, use a reliable form of birth control (contraception) while you’re taking Volibris.
→ Če obstaja možnost zanositve, morate med zdravljenjem z zdravilom Volibris uporabljati zanesljivo obliko kontracepcije.
→ If you are taking the Pill on the same day as Bridion is given to you, follow the instructions for a missed dose in the Pill’s package leaflet.
→ Če vzamete tabletko isti dan, kot prejmete zdravilo Bridion, upoštevajte navodila za ravnanje v primeru izpuščenega odmerka, ki so podana v priloženem navodilu za uporabo tabletk.
→ If you become pregnant or think that you may be pregnant while you’re taking Volibris, see your doctor immediately.
→ Če med jemanjem zdravila Volibris zanosite ali mislite, da ste zanosili, se nemudoma posvetujte s svojim zdravnikom.
→ If you get any side effects, talk to your doctor or pharmacist.
→Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
→ It is especially important that you tell your anaesthetist if you have recently taken:
→ Izredno pomembno je, da anestezistu poveste, če ste pred kratkim jemali:
→ Tell your anaesthetist if this applies to you.
→ Če to velja za vas, morate to povedati anestezistu.
→ Tell your anaesthetist if you are pregnant or might be pregnant.
→ Povejte anestezistu, če ste noseči ali bi lahko bili noseči.
→ Tell your anaesthetist if you are taking, have recently taken or might take any other medicines.
→ Obvestite anestezista, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
→ Tell your doctor if any of these applies to you.
 Zdravniku morate povedati, če kaj od tega velja za vas.
→ Tell your doctor if any of these applies to you.
 Če se karkoli od navedenega nanaša na vas, o tem obvestite svojega zdravnika.
→ Tell your doctor immediately if you get any symptoms of these conditions, as hospitalisation may be necessary.
 Če opazite kateregakoli od simptomov navedenih stanj, o tem nemudoma obvestite svojega zdravnika, saj bo morda potrebno zdravljenje v bolnišnici.
↓ 12% ↓ 16%
500 na 12 ur, ↓ 12 % ↓ 16
↓ amprenavir
↓ amprenavirja
↓ citalopram,
↓ metilprednizolon,
↓ cycloben- zaprine
↓ ciklobenzapri n
↓ cyclobenzapr ine
↓ ciklobenzaprin
↓ darunavir
↓ darunavirja
↓ dasabuvir
↓ ombitasvir
↓ efavirenz (+ TVR
↓ efavirenza (+ TVR
↓ erythromycin
↓ ibuprofen
↓ escitalopram
↓ escitaloprama
↓ ethinylestradiol
↓ etinilestradiola
↓ fluconazole
↓ esomeprazol,
↓ itraconazole,
↓ ciclosporin,
↓ IVA
↓ bupropion
↓ ombitasvir
CYP3A4/CYP2
↓ ombitasvir
dasabuvirja
↓ paritaprevir
Moorda bo potrebno
↓ R-methadone
AUC 0,71 (0,66-0,76)
↓ repaglinide A higher dose of repaglinide may be
↓ repaglinid Mogoče bo potreben večji odmerek
↓ rifabutin
podbujanja ali
↓ telaprevir
↓ telaprevirja
↓ telaprevir 1,125 mg every
↓ telaprevirja 1.125 mg na
↓ telaprevir 750 mg q8h
↓ telaprevir 750 mg na 8 h
↓ telaprevir 750 mg q8h
↓ telaprevir 750 mg na8 h
↓ telaprevir induction of CYP3A
↓ telaprevirja zaviranje CYP3A
↓diazepam
tudi o prilagoditvi
↓ombitasvir
(glejte poglavje
↓ombitasvir
dasabuvirja
↓When should you step down?
↓Kdaj je treba odmerek zmanjšati?
↔ AUC 0.99 (0.82, 1.20)
↑ AUC 4,53 (3,26; 6,30)
↔ AUC 1.03 (0.90, 1.18)
↔ AUC 0,98 (0,85; 1,14)
↔ AUC 1.06 (0.92, 1.21)
↑ AUC 1,09 (0,84; 1,40)
↔ AUC 1.09 (0.94, 1.26)
↔ AUC 1,00 (0,87; 1,13)
↔ AUC 1.20 (1.04, 1.39)
↔ AUC 1,04 (0,90; 1,20)
↔ Cmax 1.03 (0.87, 1.23)
↑ Cmax 2,54 (1,87; 3,45)
↔ Cmax 1.07 (0.94, 1.22)
↓ Cmax 0,73 (0,59; 0,90)
↔ Cmax 1.15 (0.97, 1.36)
↔ Cmax 0,97 (0,83; 1,14)
↔ ombitasvir
(0,82-0,93)
↔ ombitasvir
0,93
↔ ombitasvir
1,15
↔ ombitasvir
paritaprevirjem,
↔ ombitasvir
UPORABL JENO Z
↔ ombitasvir
↑ paritaprevir
↔ paritaprevir
50 %.
↔ paritaprevir
UPORABL JENO Z
↘ Open Here
“odprite tukaj”
∞ Not reached (i.e. the median was not reached)
∞ Ni doseženo (t.j., mediana ni bila dosežena).
≤ 0.125 mg/l; Resistant > 0.125 mg/l.
≤ 0,125 mg/l; odporni > 0,125 mg/l.
≤ 0.75 x 109/l on a VELCADE dosing day (other than day 1)
≤ 30 x 109/l ali ANC ≤ 0,75 x 109/l
≤ 100 kg.
Nosečnost
≤ 100,000 copies/ml
≤ 100,000 kopij/ml
≤ 100,000 copies/ml
≤ 100.000 kopij/ml
≤ 100,000 copies/mL.
≤ 100.000 kopij/ml.
≤ 12000 MBq at ToC (see outer packaging)
≤ 12000 MBq ob ToC (glejte zunanjo ovojnino).
≤ 200 cells/mm3
≤ 200 celic/mm3
≤ 200 mg once daily
≤ 200 mg enkrat dnevno
≤ 25%.
NNRTI-ji/efavirenz
≤ 25,000/l during the study, including 14% < 10,000/l; in contrast, with a baseline platelet count
< 75.000/l, je med preskušanjem imelo število trombocitov ≤ 25.000/l (vključno s 14% bolnikov, ki so imeli število trombocitov < 10.000/l).
≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/µL, 50-199 cells/µL, or ≥ 200 cells/µL), and by region (US or ex US).
> 100.000 kopij/ml do ≤ 400.000 kopij/ml ali > 400.000 kopij/ml), po številu celic CD4+ (< 50 celic/μl, 50–199 celic/μl ali ≥ 200 celic/μl) in po regiji (ZDA ali zunaj ZDA).
≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/μL, 50-199 cells/μL, or ≥ 200 cells/μL), and by region (US or ex-US).
> 100.000 kopij/ml do ≤ 400.000 kopij/ml ali > 400.000 kopij/ml), po številu celic CD4+ (< 50 celic/μl, 50-199 celic/μl ali ≥ 200 celic/μl) in po regiji (ZDA ali zunaj ZDA).
≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/μL, 50-199 cells/μL, or ≥ 200 cells/μL), and by region (US or ex-US).
> 100.000 kopij/ml do ≤ 400.000 kopij/ml ali > 400.000 kopij/ml), po številu celic CD4+ (< 50 celic/μl, 50–199 celic/μl ali ≥ 200 celic/μl) in po regiji (ZDA ali zunaj ZDA).
≤ 50 kg Body Weight
telesna masa ≤ 50 kg
≤ 50 ml/min) or with moderate to severe hepatic impairment (Child-Pugh score > 6) (see sections 4.3, 4.4 and 5.2).
≤ 50 ml/min) ali z zmerno do hudo okvarjenim delovanjem jeter (število točk po Child-Pughu ≥ 6) kontraindiciran (glejte poglavja 4.3, 4.4 in 5.2).
≤ 7.5 mg/dl (1.9 mmol/l) or persistent symptoms of hypocalcaemia and Vitamin D cannot be increased
≤ 7,5 mg/dl (1,9 mmol/l) ali persistentni simptomi hipokalciemije, vitamina D pa ni mogoče zvišati
≤ Grade 1 (< 1.5 x IULN) Recurrence at 15 mg:
≤ 1. stopnjo (< 1,5 x IULN) začnite z odmerkom 15 mg Ponovni pojavi pri 15 mg:
≤ Grade 1 (< 1.5 x IULN) Recurrence at 15 mg:
≤ 1. stopnjo(< 1,5 x IULN) začnite z odmerkom 15 mg Ponovni pojavi pri 15 mg:
≤ Grade 1 (< 1.5 x IULN) Recurrence at 30 mg:
≤ 1. stopnjo (< 1,5 x IULN) začnite z odmerkom 30 mg Ponovni pojav pri 30 mg:
≤ Grade 1 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE])
≤ razred 1 (Merila pogostih toksičnosti Nacionalnega inštituta za rakava obolenja; National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE])
≤ Grade 1; resume at next lower dose levela
≤ 1. stopnjo; nadaljujte z naslednjo nižjo ravnijo odmerkaa
≤1 year
≤ 1 leto
≤10 ml or 20 ml syringe for administration of volumes of >10 ml)
≤ 10 ml ali 20 ml brizga za odmerjanje količin > 10 ml)
≤2,000 µg/l
≤2.000 µg/l
≤20 times ULN (Grade 3)
≤ 20-kratnik ULN (stopnja 3)
≤28500 MBq at ToC (see outer packaging)
≤ 28500 MBq ob ToC (glejte zunanjo ovojnino).
≤2xULN (N=138)
≤2xZMN (N=138)
≤5 times upper limit of normal (ULN) (maximum Grade 2)
≤ 5-kratnik zgornje normalne vrednosti (ULN - Upper Limit of Normal) (največ stopnja 2)
≤5 years
≤ 5 let
≤5.5 mmol/l (≤100 mg/dl) Target
≤ 5,5 mmol/l (≤ 100 mg/dl) cilj
≤95 mmHg, and patient has been on a stable dose of antihypertensive therapy for at least 48 hours, resume lenvatinib at a reduced dose (see section 4.2)
≤95 mmHg, bolnik pa je že vsaj 48 ur na stabilnem odmerku antihipertenzivne terapije, spet začnite dajati lenvatinib v zmanjšanem odmerku (glejte poglavje 4.2).
≤ULN (N=188)
≤ZMN (N=188)
≥ 0.2% of subjects and ≥ 0.1% more and at least 3 more subjects treated with dapagliflozin 10 mg compared to placebo.
≥ 0,2 % preiskovancev ter pri ≥ 0,1 % več in pri vsaj 3 preiskovancih več med uporabo 10 mg dapagliflozina kot med uporabo placeba.
≥ 0.5 and < 1.5 x 109/l
 0,5 in < 1,5 x 109/l
≥ 0.5 x 109/l, and
≥ 0,5 x 109/l in
≥ 0.5 x 109/l, and < 0.75 x 109/l
≥ 0,5 x 109/l in < 0,75 x 109/l
≥ 0.5 x 109/l, and < 0.75 x 109/l
≥ 0,5 x 109/l in< 0,75 x 109/l
≥ 1 mg/dl (0.25 mmol/l) decrease from baseline in mean corrected total serum calcium concentration, when compared with the placebo treated patients (75.8% versus 0% and 84.8% versus 5.9% respectively).
≤ 10,3 mg/dl (2,57 mmol/l) in≥ 1 mg/dl (0,25 mmol/l) znižanje od povprečne korigirane celotne koncentracije kalcija v serumu v primerjavi z izhodiščem (75,8 % v primerjavi z 0 % in 84,8 % v primerjavi s 5,9 %).
≥ 1-log10 decline
≥ 1-log10 zmanjšanje
≥ 1.0 log10 decrease from baseline in plasma viral load
Zmanjšanje kopij v plazmi za ≥ 1.0 log10 glede na začetno vrednost
≥ 1.0 x 109/l, and
≥ 1,0 x 109/l in
≥ 1/1,000 to
≥ 1/1.000
≥ 1/1,000 to
≥ 1/1.000 do
≥ 1/1,000 to < 1/100, rare ≥1/10,000 to <1/1,000, very rare < 1/10,000).
<1/10, občasni ≥1/1.000 do <1/100, redki ≥1/10.000 do <1/1.000, zelo redki <1/10.000).
≥ 1/10
neznana
≥ 1/10
Organski sistem
≥ 1/10,000 to
≥ 1/10.0
≥ 1/10,000 to
≥ 1/10.000
≥ 1/10,000 to <1/1000
≥ 1/10.000 do < 1/1.000
≥ 1/100 to
≥ 1/100 do
≥ 1/1000 to
≥ 1/1.000 do
≥ 1/1000 to
≥ 1/1000 do
≥ 10 and < 100 x 109/l
 10 in < 100 x 109/l
≥ 100,000 copies/ml
≥ 100.000 kopij/ml